Today’s Stock Market in 2-Minutes
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026
Patrick Gruber, CEO of Gevo (NASDAQ: GEVO), shares how the company is pioneering renewable, drop-in hydrocarbon jet fuels that are cost-competitive with traditional petroleum-based alternatives. With over 450 patents and projects backed by a $1.63B DOE loan guarantee, Gevo is scaling commercial production through facilities in South Dakota and North Dakota. The company’s ethanol-based jet fuel, carbon capture, and RNG assets are unlocking significant revenue streams—positioning Gevo to become EBITDA positive in 2025. With $270M+ in cash, strategic partnerships, and bipartisan support for 45Z tax credits, Gevo is accelerating the transition to net-zero aviation fuels.
May 22, 2025VANCOUVER, British Columbia, June 09, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces the company been added as a member of the broad-market Russell 3000® Index effective […]
June 9, 2026
AVENTURA, Fla., June 08, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, announced today that it has rapidly delivered against a U.S. Army order for its Threat Analysis “Kit” under an award valued at approximately $743,000. […]
June 8, 2026
WEST HOLLYWOOD, Calif., June 09, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), an advanced sensing technology company developing AI-driven, RF-based sensing and computational acceleration technologies for defense and commercial uses, today announced it has executed a definitive agreement with respect to the proposed strategic acquisition of controlling interest in Foresight Autonomous […]
June 9, 2026
WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio Clinical trial expected to initiate in 2H 2026 using mRNA payload […]
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026
June 9, 2026